

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Orbifloxacin / Posaconazole / Mometasone Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-  
stance/Mixture : Veterinary product

Recommended restrictions  
on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Walton Manor, Walton  
MK7 7AJ Milton Keynes - United Kingdom

Telephone : +1-908-740-4000

E-mail address of person  
responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

**Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK  
SI 2019/720, and UK SI 2020/1567)**

Eye irritation, Category 2 H319: Causes serious eye irritation.

Long-term (chronic) aquatic hazard, Category 2 H411: Toxic to aquatic life with long lasting effects.

#### 2.2 Label elements

**Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI  
2019/720, and UK SI 2020/1567)**

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

Hazard pictograms :

Signal word : Warning

Hazard statements : H319 Causes serious eye irritation.  
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P264 Wash skin thoroughly after handling.  
P273 Avoid release to the environment.  
P280 Wear eye protection/ face protection.  
**Response:**  
P337 + P313 If eye irritation persists: Get medical advice/  
attention.  
P391 Collect spillage.

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Orbifloxacin	113617-63-3	Repr. 2; H361d	$\geq 1 - < 3$
Posaconazole	171228-49-2	Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 1; H372 (Adrenal gland, Bone marrow, Kid- ney, Liver, Nervous system, Reproduc- tive organs) Aquatic Acute 1; H400 Aquatic Chronic 1; H410	$\geq 0.1 - < 0.25$

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version 4.1      Revision Date: 14.04.2025      SDS Number: 9372520-00010      Date of last issue: 03.12.2024  
Date of first issue: 27.08.2021

		M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1	
Mometasone	83919-23-7	Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410  M-Factor (Chronic aquatic toxicity): 100	$\geq 0.1 - < 0.25$

For explanation of abbreviations see section 16.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

### 4.2 Most important symptoms and effects, both acute and delayed

Risks : Causes serious eye irritation.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

barriers).  
Retain and dispose of contaminated wash water.  
If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800 807060).

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing. Do not breathe vapours or spray mist. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Keep tightly closed.  
Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

### 7.3 Specific end use(s)

Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Orbifloxacin	113617-63-3	TWA	0.2 mg/m <sup>3</sup> (OEB 2)	Internal
Posaconazole	171228-49-2	TWA	300 µg/m <sup>3</sup> (OEB 2)	Internal
Mometasone	83919-23-7	TWA	1 µg/m <sup>3</sup> (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm <sup>2</sup>	Internal

### 8.2 Exposure controls

#### Engineering measures

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

#### Personal protective equipment

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Filter should conform to BS EN 14387
Filter type	:	Combined particulates and organic vapour type (A-P)

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Appearance	:	suspension
Colour	:	white to off-white
Odour	:	odourless
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version 4.1	Revision Date: 14.04.2025	SDS Number: 9372520-00010	Date of last issue: 03.12.2024 Date of first issue: 27.08.2021
----------------	------------------------------	------------------------------	---

Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

### 9.2 Other information

Particle size	:	Not applicable
---------------	---	----------------

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions	:	Can react with strong oxidizing agents.
---------------------	---	---

### 10.4 Conditions to avoid

Conditions to avoid	:	None known.
---------------------	---	-------------

### 10.5 Incompatible materials

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

### SECTION 11: Toxicological information

#### 11.1 Information on toxicological effects

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

##### Acute toxicity

Not classified based on available information.

##### Product:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Remarks: No significant adverse effects were reported  
No mortality observed at this dose.

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Remarks: No significant adverse effects were reported

##### Components:

##### **Orbifloxacin:**

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg  
Remarks: No mortality observed at this dose.

LD50 (Mouse): > 2,000 mg/kg  
Remarks: No mortality observed at this dose.

LD50 (Dog): > 600 mg/kg  
Symptoms: Vomiting  
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 200 mg/kg  
Application Route: Intramuscular

LD50 (Mouse): 500 mg/kg  
Application Route: Intramuscular

LD50 (Rat): 233 mg/kg  
Application Route: Intravenous

LD50 (Mouse): 250 mg/kg  
Application Route: Intravenous

##### **Posaconazole:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

---

LD50 (Mouse): > 3,000 mg/kg  
Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

### **Mometasone:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg  
Application Route: Subcutaneous  
Symptoms: Breathing difficulties

### **Skin corrosion/irritation**

Not classified based on available information.

### **Product:**

Species : Rabbit  
Result : Mild skin irritation

### **Components:**

#### **Orbifloxacin:**

Species : Rabbit  
Method : Draize Test  
Result : No skin irritation

#### **Posaconazole:**

Species : Rabbit  
Result : No skin irritation

#### **Mometasone:**

Species : Rabbit  
Result : No skin irritation

### **Serious eye damage/eye irritation**

Causes serious eye irritation.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

### **Product:**

Species	:	Rabbit
Result	:	Mild eye irritation

### **Components:**

#### **Orbifloxacin:**

Species	:	Rabbit
Method	:	Draize Test
Result	:	Mild eye irritation

#### **Posaconazole:**

Species	:	Rabbit
Result	:	Mild eye irritation

#### **Mometasone:**

Species	:	Rabbit
Result	:	No eye irritation

### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

### **Product:**

Test Type	:	Magnusson-Kligman-Test
Exposure routes	:	Dermal
Result	:	Not a skin sensitizer.

### **Components:**

#### **Orbifloxacin:**

Test Type	:	Maximisation Test
Exposure routes	:	Dermal
Species	:	Guinea pig
Result	:	Not a skin sensitizer.

#### **Posaconazole:**

Test Type	:	Magnusson-Kligman-Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Result	:	negative

#### **Mometasone:**

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

Test Type	: Maximisation Test
Exposure routes	: Dermal
Species	: Guinea pig
Assessment	: Does not cause skin sensitisation.
Result	: negative
Remarks	: The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Orbifloxacin:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: equivocal
-----------------------	---

Test Type: Mouse Lymphoma  
Result: positive

Test Type: Chromosomal aberration  
Test system: Human lymphocytes  
Result: positive

Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Intraperitoneal injection Result: negative
----------------------	--

Test Type: unscheduled DNA synthesis assay  
Species: Rat  
Cell type: Liver cells  
Application Route: Oral  
Result: negative

Germ cell mutagenicity- Assessment	: Weight of evidence does not support classification as a germ cell mutagen.
------------------------------------	--

#### Posaconazole:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	--

Test Type: Chromosomal aberration  
Result: negative

Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Intravenous Result: negative
----------------------	--

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

### Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: positive

Test Type: Mouse Lymphoma  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

Test Type: Chromosomal aberration  
Species: Rat  
Cell type: Bone marrow  
Result: negative

Test Type: unscheduled DNA synthesis assay  
Species: Rat  
Cell type: Liver cells  
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

### Carcinogenicity

Not classified based on available information.

### Components:

#### Orbifloxacin:

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
NOAEL : 200 mg/kg body weight  
Result : negative

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
NOAEL : 200 mg/kg body weight  
Result : negative

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

---

### Posaconazole:

Species	: Rat
Application Route	: oral (feed)
Exposure time	: 2 Years
Result	: positive
Remarks	: The mechanism or mode of action is not relevant in humans.

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
Result	: positive
Remarks	: The mechanism or mode of action is not relevant in humans.

### Mometasone:

Species	: Rat
Application Route	: Inhalation
Exposure time	: 2 Years
Dose	: 0.067 mg/kg body weight
Result	: negative

Species	: Mouse
Application Route	: Inhalation
Exposure time	: 19 Months
Dose	: 0.160 mg/kg body weight
Result	: negative

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Orbifloxacin:

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity - Parent: NOAEL: 50 mg/kg body weight Early Embryonic Development: NOAEL: 50 mg/kg body weight Result: No adverse effects
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses  Test Type: Embryo-foetal development

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

Species: Rabbit  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 20 mg/kg body weight  
Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight  
Result: No effects on early embryonic development, Embryo-toxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain

Test Type: Development  
Species: Dog  
Application Route: Oral  
Developmental Toxicity: LOAEL: 2.5 mg/kg body weight  
Result: Effects on postnatal development, Skeletal malformations

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### Posaconazole:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male  
General Toxicity - Parent: NOAEL: 180 mg/kg body weight  
Symptoms: No effects on mating performance  
Result: negative

Test Type: Fertility/early embryonic development  
Species: Rat, female  
General Toxicity - Parent: NOAEL: 45 mg/kg body weight  
Symptoms: No effects on mating performance  
Result: negative

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat, female  
Application Route: Oral  
Developmental Toxicity: LOAEL: 29 mg/kg body weight  
Result: Fetotoxicity, Malformations were observed.

Test Type: Embryo-foetal development  
Species: Rabbit, female  
Developmental Toxicity: LOAEL: 40 mg/kg body weight  
Result: Fetotoxicity

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### Mometasone:

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Subcutaneous

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

Fertility: NOAEL: 0.015 mg/kg body weight  
Symptoms: Reduced embryonic survival, Reduced foetal weight  
Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Subcutaneous  
Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight  
Result: Embryotoxic effects., Teratogenicity and developmental toxicity

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Dermal  
Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight  
Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Dermal  
Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight  
Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Subcutaneous  
Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight  
Result: Effects on newborn

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight  
Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

### STOT - single exposure

Not classified based on available information.

### Components:

#### Mometasone:

Remarks : Based on available data, the classification criteria are not met.

### STOT - repeated exposure

Not classified based on available information.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

### Components:

#### **Posaconazole:**

Exposure routes	: Ingestion
Target Organs	: Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system
Assessment	: Causes damage to organs through prolonged or repeated exposure.

#### **Mometasone:**

Exposure routes	: inhalation (dust/mist/fume)
Target Organs	: Immune system, Liver, Kidney, Skin
Assessment	: May cause damage to organs through prolonged or repeated exposure.

### **Repeated dose toxicity**

### Components:

#### **Orbifloxacin:**

Species	: Rat
NOAEL	: 20 mg/kg
LOAEL	: 80 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Testis, Liver, Kidney, spleen

Species	: Mouse
NOAEL	: 80 mg/kg
LOAEL	: 250 mg/kg
Application Route	: Oral
Exposure time	: 3 Months

Species	: Juvenile dog
NOAEL	: 50 mg/kg
LOAEL	: 250 mg/kg
Application Route	: Oral
Exposure time	: 14 Days
Target Organs	: Heart, Bone
Symptoms	: Gastrointestinal disturbance
Remarks	: mortality observed

Species	: Juvenile dog
NOAEL	: 2 mg/kg
LOAEL	: 3 mg/kg
Application Route	: Oral
Exposure time	: 90 Days
Target Organs	: Bone
Remarks	: No significant adverse effects were reported

Species	: Dog
---------	-------

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

NOAEL : 37.5 mg/kg  
Application Route : Oral  
Exposure time : 30 Days

Species : Cat  
NOAEL : 7.5 mg/kg  
LOAEL : 22.5 mg/kg  
Application Route : Oral  
Exposure time : 1 Months  
Symptoms : Gastrointestinal disturbance

### Posaconazole:

Species : Rat, female  
LOAEL : 5 mg/kg  
Application Route : Oral  
Exposure time : 6 Months  
Target Organs : Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary

Species : Dog  
LOAEL : 3 mg/kg  
Application Route : Oral  
Exposure time : 392 Days  
Target Organs : Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal cord, lymphoid tissue

Species : Monkey  
LOAEL : 15 mg/kg  
Application Route : Oral  
Exposure time : 1 Months  
Target Organs : Bone marrow, Adrenal gland, Lymph nodes, Blood

Species : Dog  
LOAEL : 3 mg/kg  
Application Route : Oral  
Exposure time : 56 Weeks  
Target Organs : Adrenal gland, Bone marrow, Kidney, Nervous system, spleen, thymus gland, Testis, lymphoid tissue

Species : Monkey  
LOAEL : 180 mg/kg  
Application Route : Oral  
Exposure time : 12 Months  
Target Organs : Blood, Gastrointestinal tract, spleen

Species : Monkey  
LOAEL : 8 mg/kg  
Application Route : Intravenous  
Exposure time : 1 Months  
Target Organs : Cardio-vascular system, Lungs, Adrenal gland, Blood

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

### Mometasone:

Species : Rat  
NOAEL : 0.005 mg/kg  
LOAEL : 0.3 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog  
LOAEL : 0.5 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat  
NOAEL : 0.00013 mg/l  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 90 d  
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species : Dog  
NOAEL : 0.0005 mg/l  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 90 d  
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

### Aspiration toxicity

Not classified based on available information.

### Components:

#### Mometasone:

Not applicable

### Experience with human exposure

### Components:

#### Orbifloxacin:

Ingestion : Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash  
Remarks: May cause photosensitisation.

#### Posaconazole:

Ingestion : Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhoea, hypertension, neutropenia, electrolyte imbalance

#### Mometasone:

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

### Further information

#### Components:

#### **Mometasone:**

Remarks : Dermal absorption possible

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

#### **Posaconazole:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.276 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.509 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 1

Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 0.206 mg/l  
Exposure time: 33 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.244 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211  
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 1

### Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l  
Exposure time: 96 h  
Remarks: No toxicity at the limit of solubility  
  
LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l  
Exposure time: 7 d  
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 5 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility  
  
EC50 (Americamysis): > 5 mg/l  
Exposure time: 96 h  
Method: US-EPA OPPTS 850.1035  
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility  
  
NOEC : 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity) : NOEC: 0.00014 mg/l  
Exposure time: 32 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210

Toxicity to daphnia and other : NOEC: 0.34 mg/l

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

aquatic invertebrates (Chronic toxicity)	Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility
--	--

M-Factor (Chronic aquatic toxicity)	: 100
-------------------------------------	-------

### 12.2 Persistence and degradability

#### Components:

##### **Posaconazole:**

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 h Method: OECD Test Guideline 314
Stability in water	: Degradation half life (DT50): > 30 d Method: OECD Test Guideline 111

##### **Mometasone:**

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 d Method: OECD Test Guideline 314
Stability in water	: Hydrolysis: 50 % (12 d) Method: OECD Test Guideline 111

### 12.3 Bioaccumulative potential

#### Components:

##### **Posaconazole:**

Bioaccumulation	: Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 20 Method: OECD Test Guideline 305
-----------------	---

Partition coefficient: n-octanol/water	: log Pow: 4.15
--	-----------------

##### **Mometasone:**

Bioaccumulation	: Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 107.1 Method: OECD Test Guideline 305
-----------------	--

Partition coefficient: n-octanol/water	: log Pow: 4.68
--	-----------------

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

### 12.4 Mobility in soil

#### Components:

##### **Posaconazole:**

Distribution among environmental compartments : log Koc: 5.52

##### **Mometasone:**

Distribution among environmental compartments : log Koc: 4.02

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Other adverse effects

#### Product:

Endocrine disrupting potential : This substance/mixture does not contain components considered to have endocrine disrupting properties for environment according to UK REACH Article 57(f).

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

## SECTION 14: Transport information

### 14.1 UN number

ADN	: UN 3082
ADR	: UN 3082
RID	: UN 3082
IMDG	: UN 3082

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

**IATA** : UN 3082

### 14.2 UN proper shipping name

**ADN** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,  
N.O.S.  
(Mometasone, Posaconazole)

**ADR** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,  
N.O.S.  
(Mometasone, Posaconazole)

**RID** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,  
N.O.S.  
(Mometasone, Posaconazole)

**IMDG** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,  
N.O.S.  
(Mometasone, Posaconazole)

**IATA** : Environmentally hazardous substance, liquid, n.o.s.  
(Mometasone, Posaconazole)

### 14.3 Transport hazard class(es)

	Class	Subsidiary risks
<b>ADN</b>	: 9	
<b>ADR</b>	: 9	
<b>RID</b>	: 9	
<b>IMDG</b>	: 9	
<b>IATA</b>	: 9	

### 14.4 Packing group

**ADN**  
Packing group : III  
Classification Code : M6  
Hazard Identification Number : 90  
Labels : 9

**ADR**  
Packing group : III  
Classification Code : M6  
Hazard Identification Number : 90  
Labels : 9  
Tunnel restriction code : (-)

**RID**  
Packing group : III  
Classification Code : M6  
Hazard Identification Number : 90  
Labels : 9

**IMDG**

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

Packing group : III  
Labels : 9  
EmS Code : F-A, S-F

### IATA (Cargo)

Packing instruction (cargo aircraft) : 964  
Packing instruction (LQ) : Y964  
Packing group : III  
Labels : Miscellaneous

### IATA (Passenger)

Packing instruction (passenger aircraft) : 964  
Packing instruction (LQ) : Y964  
Packing group : III  
Labels : Miscellaneous

## 14.5 Environmental hazards

### ADN

Environmentally hazardous : yes

### ADR

Environmentally hazardous : yes

### RID

Environmentally hazardous : yes

### IMDG

Marine pollutant : yes

### IATA (Passenger)

Environmentally hazardous : yes

### IATA (Cargo)

Environmentally hazardous : yes

## 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17) : Conditions of restriction for the following entries should be considered:

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

UK REACH Candidate list of substances of very high concern (SVHC) for Authorisation	:	Not applicable
The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Britain)	:	Not applicable
Regulation (EU) No 2024/590 on substances that deplete the ozone layer	:	Not applicable
UK REACH List of substances subject to authorisation (Annex XIV)	:	Not applicable
GB Export and import of hazardous chemicals - Prior Informed Consent (PIC) Regulation	:	Not applicable
Control of Major Accident Hazards Regulations 2015 (COMAH)	:	Not applicable

E2	ENVIRONMENTAL HAZARDS	Quantity 1 200 t	Quantity 2 500 t
----	--------------------------	---------------------	---------------------

### Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to new and expectant mothers at work contained in Regulation 16 to 18) and of the Pregnant Workers Directive 92/85/EEC.

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

### The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	---	--

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

### Full text of H-Statements

H319	: Causes serious eye irritation.
H360Df	: May damage the unborn child. Suspected of damaging fertility.
H361d	: Suspected of damaging the unborn child.
H372	: Causes damage to organs through prolonged or repeated exposure if swallowed.
H373	: May cause damage to organs through prolonged or repeated exposure if inhaled.
H400	: Very toxic to aquatic life.
H410	: Very toxic to aquatic life with long lasting effects.

### Full text of other abbreviations

Aquatic Acute	: Short-term (acute) aquatic hazard
Aquatic Chronic	: Long-term (chronic) aquatic hazard
Eye Irrit.	: Eye irritation
Repr.	: Reproductive toxicity
STOT RE	: Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
4.1	14.04.2025	9372520-00010	Date of first issue: 27.08.2021

---

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Eye Irrit. 2	H319
Aquatic Chronic 2	H411

### Classification procedure:

Based on product data or assessment  
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN